IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.277
NA - Nord America 5.542
AS - Asia 5.085
SA - Sud America 788
AF - Africa 68
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 2
Totale 23.780
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.154
US - Stati Uniti d'America 5.441
SG - Singapore 1.803
IE - Irlanda 1.252
CN - Cina 1.024
HK - Hong Kong 814
IT - Italia 793
BR - Brasile 650
VN - Vietnam 625
DE - Germania 457
GB - Regno Unito 426
UA - Ucraina 356
KR - Corea 295
FR - Francia 284
IN - India 145
FI - Finlandia 142
SE - Svezia 115
GR - Grecia 106
TR - Turchia 101
JP - Giappone 81
CA - Canada 58
AR - Argentina 53
NL - Olanda 38
AT - Austria 37
BD - Bangladesh 36
PK - Pakistan 36
MX - Messico 29
EC - Ecuador 28
IQ - Iraq 25
ID - Indonesia 23
PL - Polonia 22
BE - Belgio 21
ZA - Sudafrica 17
CZ - Repubblica Ceca 16
ES - Italia 16
MA - Marocco 14
AU - Australia 11
VE - Venezuela 11
KE - Kenya 9
PY - Paraguay 9
BO - Bolivia 8
CH - Svizzera 8
CL - Cile 8
CO - Colombia 8
PE - Perù 8
IR - Iran 7
NZ - Nuova Zelanda 7
PH - Filippine 7
SA - Arabia Saudita 7
AZ - Azerbaigian 6
KG - Kirghizistan 6
LT - Lituania 6
TN - Tunisia 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
IL - Israele 5
JO - Giordania 5
HU - Ungheria 4
NP - Nepal 4
SN - Senegal 4
UY - Uruguay 4
DO - Repubblica Dominicana 3
EG - Egitto 3
MK - Macedonia 3
RO - Romania 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AL - Albania 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
ET - Etiopia 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
HN - Honduras 2
JM - Giamaica 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
OM - Oman 2
RS - Serbia 2
TW - Taiwan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CI - Costa d'Avorio 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
PT - Portogallo 1
Totale 23.773
Salva come PNG Salva come JPEG
Città #
Moscow 2.983
Dublin 1.237
Hong Kong 801
Singapore 789
San Jose 716
Santa Clara 683
Chandler 607
Jacksonville 581
Seoul 271
Ashburn 238
Ho Chi Minh City 204
Beijing 177
Princeton 170
New York 149
Bremen 145
Roxbury 142
Hanoi 141
Naples 134
Medford 131
Dallas 128
Hefei 128
Ann Arbor 106
Munich 105
Los Angeles 87
The Dalles 84
Bengaluru 78
Wilmington 78
Caserta 76
São Paulo 71
Boardman 54
Cambridge 45
Des Moines 42
San Mateo 41
Nanjing 39
Da Nang 36
Woodbridge 36
Haiphong 35
Council Bluffs 33
Napoli 32
Turku 32
Nuremberg 30
Amsterdam 22
Elora 22
Falkenstein 22
Vienna 22
Brussels 21
Tianjin 21
Brasília 20
Dong Ket 20
Norwalk 20
Rio de Janeiro 20
Helsinki 19
Tokyo 19
Orem 18
Shanghai 18
Warsaw 18
Houston 17
Mountain View 17
Hải Dương 16
Frankfurt am Main 15
Milan 15
Brooklyn 14
Guangzhou 14
Nanchang 14
Atlanta 13
Belo Horizonte 13
Brno 13
Columbus 13
Curitiba 12
Quito 12
Aversa 11
Chennai 11
Istanbul 11
Jakarta 11
London 11
Manchester 11
Rome 11
Chicago 10
Düsseldorf 10
Lappeenranta 10
Ninh Bình 10
Redwood City 10
San Francisco 10
Auburn Hills 9
Changsha 9
Giugliano in Campania 9
Hillsboro 9
Jinan 9
Montreal 9
Bahawalpur 8
Biên Hòa 8
Ercolano 8
Guarulhos 8
Guayaquil 8
Hangzhou 8
Mumbai 8
Nairobi 8
Rawalpindi 8
Zhengzhou 8
Can Tho 7
Totale 12.473
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 244
Beyond N staging in colorectal cancer: Current approaches and future perspectives 219
ONCOLOGIA MEDICA 206
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 201
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 201
AXL is an oncotarget in human colorectal cancer 194
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 190
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 182
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 181
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 181
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 178
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 177
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 177
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 170
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 170
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 169
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 164
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 163
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 161
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 160
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 158
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 158
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 158
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 157
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 157
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 156
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 154
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 154
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 150
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 149
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 149
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 149
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 148
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 146
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 145
The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria 144
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 144
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 144
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 144
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 144
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 142
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 141
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 140
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 139
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 139
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 139
Farmacogenomica e cancro colorettale 137
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 136
Light alcohol drinking and the risk of cancer development: a controversial relationship 135
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 134
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 134
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 133
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 132
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 131
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 130
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 130
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 130
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 129
TRASTUZUMAB RESISTANCE IN BREAST CANCER 128
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 128
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 127
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 127
Pimasertib hydrochloride 127
Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report 126
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 126
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 126
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)] 125
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 124
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 124
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 124
Endoscopic calcium electroporation for unfit-for-surgery bleeding colorectal cancer: the dawn of a new treatment? 124
Targeting EGFR in Pancreatic Cancer Treatment. 123
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 123
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 123
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ 123
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 122
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 122
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 121
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 120
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 120
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 120
Chemoradiotherapy as adjuvant treatment of gastric cancer 120
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 120
Prevention of cardiovascular complications in elderly cancer patients 119
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 119
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 118
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 117
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 117
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 117
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 116
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 116
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 115
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 115
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 115
Totale 14.349
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.726
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.726
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021287 0 0 0 0 0 0 0 0 0 116 120 51
2021/20221.151 54 17 23 23 340 20 42 35 54 99 106 338
2022/20232.473 251 50 34 212 291 208 7 151 1.149 17 57 46
2023/2024992 93 37 38 51 335 140 19 24 11 14 74 156
2024/20253.318 56 105 54 107 471 432 339 320 471 448 268 247
2025/202613.564 559 606 669 682 1.097 7.587 705 749 606 304 0 0
Totale 24.288